eFFECTOR Therapeutics(EFTR)
$0.000.00 (0.00%)
EFTR
eFFECTOR Therapeutics financials statements
$0.00
At close:0.00 (0.00%)
Want to see EFTR full AI Analyst Report?
eFFECTOR Therapeutics (EFTR) Ratios
264 Followers
eFFECTOR Therapeutics Ratios
EFTR's free cash flow for Q1 2024 was $-7.28M. For the 2024 fiscal year, EFTR's free cash flow was increased by $0.00 and operating cash flow was $-7.28M. See a summary of the company’s cash flow.
| Ratios | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.77 | 1.12 | 13.30 | 1.89 | 0.23 |
| Quick Ratio | 0.77 | 1.12 | 13.32 | 1.89 | 0.23 |
| Cash Ratio | 0.58 | 0.35 | 12.49 | 1.73 | 0.18 |
| Solvency Ratio | -1.36 | -0.51 | 0.43 | 0.10 | -1.55 |
| Operating Cash Flow Ratio | -1.15 | -1.03 | -6.26 | 1.58 | -1.46 |
| Short-Term Operating Cash Flow Coverage | -1.44 | -1.28 | -565.64 | 2.34 | -1.81 |
| Net Current Asset Value | $ -6.50M | $ 2.83M | $ 16.12M | $ -132.37M | $ -14.66M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.00 | 0.70 | 0.37 | 0.78 | 2.99 |
| Debt-to-Equity Ratio | -3.55 | 5.21 | 1.16 | 13.24 | -1.10 |
| Debt-to-Capital Ratio | 1.39 | 0.84 | 0.54 | 0.93 | 10.84 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.02 | 0.53 | 0.88 | 0.00 |
| Financial Leverage Ratio | -3.55 | 7.46 | 3.13 | 17.06 | -0.37 |
| Debt Service Coverage Ratio | -1.60 | -0.47 | 9.73 | 2.17 | -1.69 |
| Interest Coverage Ratio | 0.00 | -14.39 | -18.89 | 11.87 | -20.71 |
| Debt to Market Cap | 0.80 | 1.15 | 0.06 | 0.09 | 1.11 |
| Interest Debt Per Share | 9.39 | 13.68 | 13.49 | 23.88 | 301.38 |
| Net Debt to EBITDA | -0.17 | -0.57 | -1.69 | -0.14 | -0.42 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 98.51% | 98.32% | 100.00% | 0.00% |
| EBIT Margin | 0.00% | -574.56% | 1228.11% | 37.85% | 0.00% |
| EBITDA Margin | 0.00% | -573.07% | 1229.79% | 38.23% | 0.00% |
| Operating Profit Margin | 0.00% | -911.99% | -2330.56% | 37.66% | 0.00% |
| Pretax Profit Margin | 0.00% | -637.91% | 1104.76% | 34.67% | 0.00% |
| Net Profit Margin | 0.00% | -363.83% | 1104.76% | 33.84% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | -363.83% | 1104.76% | 33.84% | 0.00% |
| Net Income Per EBT | 100.00% | 57.04% | 100.00% | 97.59% | 100.00% |
| EBT Per EBIT | 105.81% | 69.95% | -47.40% | 92.05% | 103.96% |
| Return on Assets (ROA) | -174.31% | -44.46% | 29.23% | 85.08% | -583.69% |
| Return on Equity (ROE) | 617.96% | -331.80% | 91.40% | 1451.58% | 214.89% |
| Return on Capital Employed (ROCE) | 644.40% | -809.67% | -66.55% | 199.61% | 206.70% |
| Return on Invested Capital (ROIC) | -221.30% | -76.30% | -66.43% | 110.74% | -2034.50% |
| Return on Tangible Assets | -174.31% | -44.46% | 29.23% | 85.08% | -583.69% |
| Earnings Yield | -140.08% | -73.41% | 4.72% | 9.54% | -216.72% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 131.59 | 14.30 | 0.00 | 0.00 |
| Payables Turnover | 0.05 | 0.04 | 0.05 | 0.00 | 0.51 |
| Inventory Turnover | 0.00 | -1.96 | -0.24 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 10.09 | 5.56 | 333.33 | 0.00 |
| Asset Turnover | 0.00 | 0.12 | 0.03 | 2.51 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.14 | 0.05 | -12.24 | 0.00 |
| Cash Conversion Cycle | -7661.71 | -10416.94 | -9342.81 | 0.00 | -710.98 |
| Days of Sales Outstanding | 0.00 | 2.77 | 25.52 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | -185.94 | -1520.83 | 0.00 | 0.00 |
| Days of Payables Outstanding | 7661.71 | 10233.77 | 7847.50 | 0.00 | 710.98 |
| Operating Cycle | 0.00 | -183.17 | -1495.31 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -13.51 | -15.72 | -15.40 | 23.11 | -500.27 |
| Free Cash Flow Per Share | -13.56 | -15.84 | -15.43 | 22.86 | -500.34 |
| Dividend Paid and CapEx Coverage Ratio | -304.64 | -134.89 | -592.57 | 89.84 | -6899.50 |
| Capital Expenditure Coverage Ratio | -304.64 | -134.89 | -592.57 | 89.84 | -6899.50 |
| Operating Cash Flow Coverage Ratio | -1.44 | -1.28 | -1.24 | 1.07 | -1.81 |
| Operating Cash Flow to Sales Ratio | 0.00 | -7.29 | -17.40 | 0.33 | 0.00 |
| Free Cash Flow Yield | -115.96% | -148.17% | -7.45% | 9.19% | -201.14% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.71 | -1.36 | 21.17 | 10.48 | -0.46 |
| Price-to-Sales (P/S) Ratio | 0.00 | 4.96 | 233.87 | 3.55 | 0.00 |
| Price-to-Book (P/B) Ratio | -4.41 | 4.52 | 19.35 | 152.09 | -0.99 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.86 | -0.67 | -13.41 | 10.88 | -0.50 |
| Price-to-Operating Cash Flow Ratio | -0.87 | -0.68 | -13.44 | 10.76 | -0.50 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.01 | 0.01 | -0.10 | 0.00 |
| Enterprise Value Multiple | -0.95 | -1.43 | 17.33 | 9.13 | -0.91 |
| Enterprise Value | 31.24M | 29.18M | 304.76M | 146.64M | 25.54M |
| EV to EBITDA | -0.95 | -1.43 | 17.33 | 9.13 | -0.91 |
| EV to Sales | 0.00 | 8.21 | 213.12 | 3.49 | 0.00 |
| EV to Free Cash Flow | -1.05 | -1.12 | -12.22 | 10.72 | -0.93 |
| EV to Operating Cash Flow | -1.06 | -1.13 | -12.25 | 10.60 | -0.93 |
| Tangible Book Value Per Share | -2.65 | 2.37 | 10.70 | -220.94 | -250.86 |
| Shareholders’ Equity Per Share | -2.65 | 2.37 | 10.70 | 1.64 | -250.86 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.43 | 0.00 | 0.02 | 0.00 |
| Revenue Per Share | 0.00 | 2.16 | 0.89 | 70.17 | 0.00 |
| Net Income Per Share | -16.37 | -7.85 | 9.78 | 23.74 | -539.08 |
| Tax Burden | 1.00 | 0.57 | 1.00 | 0.98 | 1.00 |
| Interest Burden | 1.09 | 1.11 | 0.90 | 0.92 | 1.05 |
| Research & Development to Revenue | 0.00 | 6.56 | 13.96 | 0.52 | 0.00 |
| SG&A to Revenue | 0.00 | 3.56 | 9.35 | 0.10 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 1.50 | 6.06 | 0.01 | 0.00 |
| Income Quality | 0.83 | 1.14 | -1.58 | 0.97 | 0.93 |
Currency in USD
